drugset / Trial / NCT00735709

Efficacy Study of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder

NCT00735709

Phase 3 Completed 560 enrolled Takeda H. Lundbeck A/S · collab
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to determine the effectiveness and safety of vortioxetine, once daily (QD), in patients with Major Depressive Disorder.

Timeline

Start
2008-08
Primary completion
2009-07
Completion
2009-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Vortioxetine Unknown 1 mg Oral
Subject Vortioxetine Unknown 5 mg Oral
Subject Vortioxetine Unknown 10 mg Oral